Skip to Content Facebook Feature Image

CityUHK team invents novel eDNA membrane to advance understanding of inshore fish diversity

Business

CityUHK team invents novel eDNA membrane to advance understanding of inshore fish diversity
Business

Business

CityUHK team invents novel eDNA membrane to advance understanding of inshore fish diversity

2026-09-14 15:11 Last Updated At:15:35

HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Monitoring marine life helps scientists track ecosystem health, improve conservation, and manage fisheries. A promising approach is environmental DNA (eDNA), which refers to trace genetic material naturally released into the water by organisms, such as skin cells, mucus and excreta. By analysing eDNA in water samples, scientists can determine which species are present in a given body of water without the need to physically capture or observe the organisms. This method is of great significance for monitoring marine ecosystems and conserving biodiversity. In practical applications, however, DNA concentrations in seawater are extremely low, making it difficult for traditional membranes to capture it effectively.

A research team from City University of Hong Kong (CityUHK), in collaboration with researchers from several other universities, has successfully developed a novel functionalised membrane that significantly improves the efficiency of collecting and detecting marine organisms' eDNA, providing a more sensitive and reliable technical tool for monitoring marine biodiversity.

The CityUHK team was led by Professor Kenneth Leung Mei-yee, Vice-President (Research) and Director of the State Key Laboratory of Marine Environmental Health (SKLMEH); and Professor Zeng Zhiyuan from the Department of Materials Science and Engineering and the SKLMEH. The study, titled "A tailored MoS2 membrane with strong DNA-binding capability enhances aquatic biota detection through environmental DNA metabarcoding", was published in the leading international journal National Science Review.

The research team coated the surface of a common membrane with an ultra-thin layer of 2D material molybdenum disulphide (MoS₂), enabling the membrane to capture DNA in water more effectively. Experimental results show that this novel membrane significantly improves the detection sensitivity of fish eDNA in both laboratory and field tests.

In controlled experiments, the researchers successfully used the membrane to accurately identify a variety of tropical coral reef fish, including Acanthurus dussumieri, Chrysiptera cyanea, Dascyllus trimaculatus, Microcanthus strigatus, and Paracanthurus hepatus.

For field testing, the research team conducted on-site sampling tests at the Hoi Ha Wan Marine Park. The results showed that the new filter membrane could detect a greater number of fish species, including anchovies, flathead gray mullet and carangid fish, without affecting the overall assessment of the fish community, demonstrating its potential for applications in practical marine monitoring.

"The membrane is simple to prepare and cost-effective, and can be directly integrated into existing water sampling filtration processes. It is expected to find future applications in marine conservation, ecological surveys and long-term environmental monitoring, and is particularly suitable for use in marine areas rich in biological resources but difficult to survey," noted Professor Leung.

He added that the Ministry of Ecology and Environment is currently promoting the use of eDNA technology in biodiversity surveys, and that the research team's innovative technology will support and drive the development of this technology.

The corresponding authors of this study include Professor Leung; Professor Zeng; Professor Huang Bolong from the Department of Chemistry at CityUHK; and Professor Qiu Jianwen from the Department of Biology at Hong Kong Baptist University. The findings demonstrate the interdisciplinary integration of advanced materials science and environmental ecology research, creating new avenues for more precise and sensitive marine biological monitoring technologies.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

CityUHK team invents novel eDNA membrane to advance understanding of inshore fish diversity

CityUHK team invents novel eDNA membrane to advance understanding of inshore fish diversity

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

Recommended Articles